You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 18, 2025

Claims for Patent: 12,291,508

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,291,508

Title:	Hydrazide containing nuclear transport modulators and uses thereof
Abstract:	The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I.
Inventor(s):	Vincent P. Sandanayaka, Sharon Shacham, Dilara McCauley, Sharon Shechter
Assignee:	Karyopharm Therapeutics Inc
Application Number:	US18/244,659
Patent Claims:	1. A method for treating a disorder associated with CRM1 activity comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of the following structural formula: and a pharmaceutically acceptable carrier. 2. The method according to claim 1, wherein the disorder is multiple myeloma. 3. The method according to claim 1, wherein the disorder is a lymphoma. 4. The method according to claim 1, wherein the method further comprises administering an effective amount of a a second therapeutic agent. 5. The method of claim 1, wherein the pharmaceutical composition is administered orally. 6. The method according to claim 2, wherein the method further comprises administering an effective amount of a second therapeutic agent. 7. The method according to claim 2, wherein the pharmaceutical composition is administered orally. 8. The method according to claim 3, wherein the method further comprises administering an effective amount of a second therapeutic agent. 9. The method according to claim 3, wherein the pharmaceutical composition is administered orally. 10. The method according to claim 1, wherein the disorder is a myelodysplastic syndrome. 11. The method according to claim 10, wherein the method further comprises administering an effective amount of a second therapeutic agent. 12. The method according to claim 10, wherein the pharmaceutical composition is administered orally. 13. The method of claim 1, wherein the disorder is a myeloproliferative disorder. 14. The method according to claim 13, wherein the method further comprises administering an effective amount of a second therapeutic agent. 15. The method according to claim 13, wherein the pharmaceutical composition is administered orally.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.